Drug Resistance to PI3K Inhibitors

[Guest guest]

Screening Identifies Mechanisms of Drug Resistance to PI3K Inhibitors

This report has significance beyond PI3K inhibitor CAL-101.

Originally found in a " CancerNetwork " publication, The link

will take you the abstract published in " Nature Chemical

Biology. " If you are female and have breast cancer or

concerns about breast cancer due to genetic predilection,

and are considering CAL-101 you might use this as a talking

point with your Oncologist, if nothing more than to get the

word out that studies such as the one conducted by Prof.

Sebastian Nijman are vital to efficacious use of expensive,

targeted drug therapies.

Quoting from the " Cancernetwork " article: " One of the most

important focuses in personalized oncology therapeutics is

on the ability to understand mechanisms of treatment

resistance, with the aim of selecting more effective

treatments. Underlying this is the need to identify tumor

mutations that are inherently resistant to a specific

treatment modality. .....Snip.........

the study also identified a new mechanism of resistance to a

group of PI3K inhibitors that are currently being

investigated in clinical trial. Many breast tumors harbor

activating mutations in the PI3K pathway. ......Snip....

[PI Prof. Sebastian Nijman " In screening thousands of

drug-gene interactions, one of our hits was the resistance

caused by activation of the NOTCH pathway and downstream

activation of c-MYC to PI3K/mTOR inhibitors. These drugs are

of great interest as many are in clinical development for a

variety of cancers. However, so far mechanisms of resistance

have not been reported”] explained professor Nijman.

http://www.cancernetwork.com/breast-cancer/content/article/10165/1958470 -

For complete cancernetwork article

http://tinyurl.com/3rmkcb8 - for PubMed abstract

I just returned from an LRF Conference in Brooklyn, NY where

it was great to see former participants and meet some my

cyber family friends. Among new acquaintances was a newly

diagnosed gal who had a history of breast cancer. Many of us

have co-morbidities of one sort or another that probably

play a part in how our CLL behaves and our reactions to

various treatments. Although the cited research does not

find direct evidence connecting PI3K inhibitor CAL-101 with

resistance in women with breast cancer, it is a much needed

step in connecting some very important dots as to the

heterogeneic pitfalls involved in the way CLL behaves and

the response we are to expect from Treatment. CAL-101 is new

and if resistance is found it will usually be encountered

down the road.

WWW